Hyoung Jin Kang

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren et al. · The Lancet Oncology · 2019 · 343 citations

Medicine, Oncology, Pharmacotherapy +17

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Lindsay Kilburn, Dong-Anh Khuong-Quang, Jordan R. Hansford et al. · Nature Medicine · 2023 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

François Doz, Cornelis M. van Tilburg, Birgit Geoerger et al. · Neuro-Oncology · 2021 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

NTRK and RET fusion–directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake

Young Ah Lee, Hyun-Jung Lee, Sun-Wha Im et al. · Journal of Clinical Investigation · 2021 · 132 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Retroviral Gene Therapy for X-linked Chronic Granulomatous Disease: Results From Phase I/II Trial

Hyoung Jin Kang, Cynthia C. Bartholomae, Anna Paruzynski et al. · Molecular Therapy · 2011 · 104 citations · Full text

Medicine, Cell Biology, Immunology +15